Tip os
Log ind
22856712.jpg
Foto: Martin Slottemo Lyngstad

BioPorto targets prominent new board member

Top picks in English:

Diagnostics company BioPorto proposes a prominent biotech profile and former CEO of the company Symphogen as a new member of its board of directors, to be officially elected at its general meeting in April.


BY ELIZABETH MØNSTED JOHANSEN
Offentliggjort 20.03.17 kl. 11:46

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

FDA panel sees cardiovascular benefits from Novo's Victoza

Novo Nordisk flag-version2.jpg Top picks in English:

With an overwhelming majority, an independent advisory committee under the US drug agency FDA has found that Novo Nordisk’s Leader study provides substantial evidence of cardiovascular risk reduction in treatment with Victoza. The result opens up the opportunity for including the data on the product’s US label.

Zealand sees big potential for SBS drug

Top picks in English:

Zealand Pharma sees a significant potential for the candidate drug glepaglutide for treatment of short bowel syndrome (SBS), which has just delivered promising phase II results. The biotech company plans to win approval and market the drug on its own, hoping it can compete with a similar product from Shire, says CEO Britt Meelby Jensen.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Leo Pharma invests in US biotech company

Top picks in English:

The Danish dermatology company Leo Pharma has pumped money into a US based biotech company developing a medical device mainly to be used in treatments of a hair loss disease. It is also the first agreement made from Leo’s newly founded hub in Boston.

Lundbeck Foundation company goes public

Top picks in English:

Lundbeckfonden Ventures’ portfolio company Bonesupport has listed on the Swedish stock market and raised SEK 500 million (about USD 57 million). The IPO puts a period to a busy half year, where two other companies have been sold. New investments are coming up, says managing partner Mette Kirstine Agger.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Forsiden lige nu

J&J vil have penge tilbage efter BMS-højesteretsdom

COLOURBOX6429704.jpg Medicinal & Biotek:

En ny højesteretsdom i USA kan gå hen og få stor betydning for medicinalselskaberne. Dommen har givet Bristol-Myers Squibb medhold i, at patienter ikke selv kan bestemme, hvor deres restssager skal føres. Det har nu fået Johnson & Johnson til at kræve omstødelse af en række sager, som har kostet farmagiganten 300 mio. dollars.

Beta Bionics vil gøre livet lettere for 80 mio diabetikere

Medico & Rehab:

Et kunstigt bugspytkirtelsystem fra et amerikansk medicoselskab, som Zealand Pharma og Novo Nordisk samarbejder med, er på vej mod markedsgodkendelse inden for de kommende år efter et vellykket forsøg med en Zealand-kandidat. Det siger adm. direktør Ed Damiano.

Bavarian fyrer i hovedkvarteret

Medicinal & Biotek:

Som led i en større effektiviseringsproces i produktionen, har Bavarian Nordic nu sat gang i en fyringsrunde i hovedkvarteret i Kvistgård. Det får ingen indflydelse på selskabets finansielle forventninger.

Zealand scorer positive resultater med kunstig bugspytkirtel

Medicinal & Biotek:

Der er kommet positive data på det fase 2a-studie, som tester brugen af Zealand Pharmas diabetesmiddel desiglucagon i amerikanske Beta Bionics kunstige bugspytkirtel. (Opdateret 9.44)

Endnu en delstat melder sig under opioidfanerne

Medicinal & Biotek:

Anklager om medskyld i en decideret opioidepidemi i USA fortsætter med at klæbe til flere store medicinalselskaber, og nu har endnu en delstat valgt at sende et søgsmål afsted mod selskaberne for blandt andet at have løjet om risici ved de omdiskuterede smertemidler.

Novartis-støttet selskab hæver mål for børsnotering

Medicinal & Biotek:

Et amerikansk biotekselskab, som har tætte forbindelser til schweiziske Novartis, satser nu på at hente op mod 900 mio. kr. i en nært forestående børsnotering.

ANNONCE
ANNONCE


ANNONCE